Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)

NCT06734884 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

DRESS Syndrome

Interventions

DRUG: Benralizumab 30 MG/ML [Fasenra]
DRUG: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride

Sponsor

University Hospital, Lille

Collaborators

[object Object]